Corrigendum to “Long-term follow-up of renal function in patients treated with migalastat for Fabry disease” [Bichet et al., MGM Reports; 28 (2021) 100786]
Daniel G. Bichet,
Roser Torra,
Eric Wallace,
Derralynn Hughes,
Roberto Giugliani,
Nina Skuban,
Eva Krusinska,
Ulla Feldt-Rasmussen,
Raphael Schiffmann,
Kathy Nicholls
Affiliations
Daniel G. Bichet
Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montreal, Quebec, Canada; Corresponding author at: Hôpital du Sacré-Coeur de Montréal, Research Center, 5400 Blvd Gouin Ouest, Montréal, Québec H4J 1C5, Canada.
Roser Torra
Inherited Renal Disorders, Nephrology Department, Fundació Puigvert, REDINREN, IIB Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Eric Wallace
Department of Medicine, University of Alabama, Birmingham, AL, USA
Derralynn Hughes
Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK
Roberto Giugliani
Medical Genetics Service, Department of Genetics, Institute of Biosciences, Institute of Basic Health Sciences, Faculty of Medicine, Faculty of Pharmacy (UFRGS) and National Institute of Population Medical Genetics (INAGEMP), Porto Alegre, Brazil
Nina Skuban
Amicus Therapeutics, Inc., Cranbury, NJ, USA
Eva Krusinska
Amicus Therapeutics, Inc., Cranbury, NJ, USA
Ulla Feldt-Rasmussen
Department of Medical Endocrinology and Metabolism, Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark
Raphael Schiffmann
Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX, USA
Kathy Nicholls
Department of Nephrology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
